AbbVie Inc. $ABBV Shares Sold by Spectrum Asset Management Inc. NB CA

Spectrum Asset Management Inc. NB CA cut its stake in AbbVie Inc. (NYSE:ABBV) by 12.0% during the 4th quarter, HoldingsChannel reports. The fund owned 18,085 shares of the company’s stock after selling 2,472 shares during the period. AbbVie comprises 1.4% of Spectrum Asset Management Inc. NB CA’s portfolio, making the stock its 25th largest position. Spectrum Asset Management Inc. NB CA’s holdings in AbbVie were worth $4,132,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after acquiring an additional 448,554 shares in the last quarter. Legal & General Group Plc raised its holdings in AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after acquiring an additional 493,420 shares in the last quarter. Wellington Management Group LLP raised its holdings in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Amundi raised its holdings in AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in AbbVie by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after acquiring an additional 408,426 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $210.29 on Wednesday. The stock has a market capitalization of $371.83 billion, a price-to-earnings ratio of 89.11, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 1-year low of $168.54 and a 1-year high of $244.81. The company’s fifty day moving average is $219.66 and its two-hundred day moving average is $223.88.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by company insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie paid US$650 million upfront to secure global rights to RemeGen’s RC148, a deal that accelerates AbbVie’s access to a partnered asset and expands its development pipeline — a clear signal management is investing in future growth. Read More.
• Positive Sentiment: AbbVie struck an exclusive licensing agreement with China’s Haisco (reports say up to ~$745M), acquiring two acute-pain assets and broadening its pain portfolio outside China — adds late-stage optionality and potential future revenue streams. Read More.
• Positive Sentiment: Late-breaking Phase II data for Elahere (mirvetuximab) in platinum‑sensitive ovarian cancer showed encouraging efficacy/safety, supporting AbbVie’s oncology growth story and increasing the commercial potential for Elahere. Read More.
• Positive Sentiment: Analysts note AbbVie’s neuroscience franchise (Botox, Vraylar) is poised for strong top-line growth in Q1, helping offset legacy declines and underpinning near-term revenue visibility. Read More.
• Positive Sentiment: Fundamentals: AbbVie recently beat quarterly EPS/revenue expectations and provided FY2026 guidance, reinforcing expectations for steady cash flow and dividend support (important context behind investor confidence). Read More.
• Neutral Sentiment: AbbV-438 myeloma trial is in Phase 1 (first-in-human) — early-stage data could support long-term oncology upside but carries the usual execution and timeline risk. Read More.
• Neutral Sentiment: Commentary on AbbVie entering the weight‑loss space notes progress but that the company remains behind market leader Eli Lilly — potential upside if AbbVie can close the gap, but outcome and timing uncertain. Read More.
• Neutral Sentiment: Corporate/brand items — marketing for Allergan Aesthetics’ Natrelle implants and a philanthropic MLB–AbbVie Foundation cancer initiative are reputational positives but unlikely to move fundamentals materially. Read More. Read More.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Cantor Fitzgerald cut their price target on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a report on Wednesday, April 8th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Barclays initiated coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price on the stock. Evercore dropped their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Finally, Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $253.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.